Answers are grounded in this paper and cite their sources.
Review summarizes Ganoderma lucidum polysaccharides' effects on diabetes complications, indicating their therapeutic potential.
Characterized by a total or partial shortage of insulin, diabetes is a chronic metabolic condition. Its widespread occurrence and related complications present a significant global public health issue. Ganoderma lucidum (Curtis) P. Karst. 1881 (Polyporaceae), a valuable traditional Chinese medicine, contains polysaccharides as its primary active metabolites. Polysaccharides exhibit virous pharmacological properties including hypoglycemic, hypolipidemic, immunomodulatory, and anti-tumor effects. Although recent research has increasingly investigated the potential of G. lucidum polysaccharides (GLPs) to manage diabetes and its complications, a systematic integration of these findings is lacking. The review comprehensively summarizes relevant literature retrieved from databases including PubMed, Sci-Hub, Science Direct, Scopus, and Open Access Library. GLPs demonstrates defensive impacts against diabetes and its associated complications including nephropathy, hepatopathy, cardiomyopathy, refractory wound healing, neuropathy, retinopathy, and erectile dysfunction--through mechanisms involving oxidative stress modulation, glucolipid metabolism regulation, anti-apoptosis, islet cells repair, and the gut microbiota remodeling. Furthermore, drug combination strategies and novel formulation development represent promising directions for future applications This review provides a theoretical foundation for the advancement of effective and low toxicity natural therapies for diabetes based on GLPs.
No takes yet. Share an insight, caveat, or question.
Xin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: